Lacosamide UCB (lacosamide)
- Region
- 🇪🇺 EU
- Active substance
- lacosamide
- Company
- UCB Pharma S.A.
- Status
- Authorised
- Therapeutic area
- Epilepsies, Partial
- CHMP opinion
- Thu 27 Jun 2019
- EU approval
- Mon 26 Aug 2019
- Application
- EMEA/H/C/005243
- ATC
- N03AX18
- Official record
- www.ema.europa.eu
Indication
Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Lacosamide Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Vimpat Authorised · UCB Pharma SA
- 🇪🇺 Lacosamide Adroiq Authorised · Extrovis EU Ltd
- 🇪🇺 Lacosamide Pain UCB Pharma Application withdrawn · UCB Pharma S.A.
Follow Lacosamide UCB
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.